ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
2seventy bio Inc

2seventy bio Inc (TSVT)

4.81
0.02
(0.42%)
At close: July 29 4:00PM
4.79
-0.02
( -0.42% )
After Hours: 4:52PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
4.79
Bid
4.47
Ask
5.00
Volume
429,955
4.635 Day's Range 4.89
1.535 52 Week Range 8.08
Market Cap
Previous Close
4.79
Open
4.70
Last Trade
1
@
4.89
Last Trade Time
16:40:50
Financial Volume
$ 2,043,869
VWAP
4.7537
Average Volume (3m)
507,894
Shares Outstanding
51,405,419
Dividend Yield
-
PE Ratio
-1.14
Earnings Per Share (EPS)
-4.23
Revenue
100.39M
Net Profit
-217.57M

About 2seventy bio Inc

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
2seventy bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TSVT. The last closing price for 2seventy bio was $4.79. Over the last year, 2seventy bio shares have traded in a share price range of $ 1.535 to $ 8.08.

2seventy bio currently has 51,405,419 shares outstanding. The market capitalization of 2seventy bio is $246.23 million. 2seventy bio has a price to earnings ratio (PE ratio) of -1.14.

TSVT Latest News

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by...

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.245.274725274734.554.894.232751374.59705372CS
40.9625.06527415143.835.0353.754976134.31508051CS
12004.795.13.545078944.25706607CS
261.5146.03658536593.286.43.139965354.80200628CS
52-3.08-39.13595933937.878.081.53513582804.06822044CS
156-21.34-81.66858017626.1344.341.5358644798.43267295CS
260-21.34-81.66858017626.1344.341.5358644798.43267295CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
IMNNImunon Inc
$ 2.26
(89.92%)
4.82M
JTAIJet AI Inc
$ 0.3994
(33.62%)
7.88M
AISPAirship AI Holdings Inc
$ 4.23
(18.49%)
494.52k
ISPOInspirato Inc
$ 6.20
(18.32%)
1.32M
TTOOT2 Biosystems Inc
$ 5.60
(18.14%)
126.35k
QXOQXO Inc
$ 11.88
(-80.36%)
1.21M
SYMSymbotic Inc
$ 29.00
(-18.61%)
754.35k
NRSNNeuroSense Therapeutics Ltd
$ 0.641
(-16.86%)
1.62k
CLDXCelldex Therapeutics Inc
$ 36.00
(-14.27%)
86.01k
BIMIBIMI International Medical Inc
$ 1.00
(-13.79%)
37.09k
NVDANVIDIA Corporation
$ 111.67
(0.07%)
8.65M
TLRYTilray Brands Inc
$ 1.99
(9.04%)
8.62M
JTAIJet AI Inc
$ 0.3994
(33.62%)
7.88M
OXLCOxford Lane Capital Corporation
$ 5.57
(0.18%)
7.49M
SPCBSuperCom Ltd
$ 0.2053
(8.05%)
5.57M

TSVT Discussion

View Posts
Monksdream Monksdream 3 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 4 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 5 months ago
TSVT 10Q due March 5
👍️0
molee molee 6 months ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 7 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1 💩 1 🤡 1
johnhancoque johnhancoque 8 months ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 9 months ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

Your Recent History

Delayed Upgrade Clock